Cessatech and Ventis Pharma announce US partnership for CT001
· Cessatech and Ventis Pharma enter a co-development and commercialization royalty license agreement for CT001 sharing net profits · CT001 will be part of US Ventis Pharma’s distribution of innovative pain management therapies under an early access program in the US · A large US market of more than 15 million pediatric injuries or procedural pain incidents, categorized as moderate to severe, giving the partnership a large market opportunity, with potential for revenues in 2024On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an